BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 16, 2007
View Archived Issues
CMS Cites EPO's Bad Rap In Plan To Curtail Reimbursement
Sales of Amgen Inc.'s blockbuster EPO products are facing a further downturn, this time thanks to the Centers for Medicare & Medicaid Services (CMS), and the company's stock on Tuesday lost 3.7 percent as a result. (BioWorld Today)
Read More
Intrexon Follows RheoGene Merger With $25M Series C1
Read More
Modigene Financing Garners $11.6M; High Hopes For CTP
Read More
CV Therapeutics Files NDA For Regadenoson Use In Stress Tests
Read More
Marcadia Raises $15M In First Round For Metabolic Programs
Read More
Other News To Note
Read More
Clinic Roundup
Read More